ASKG712

ASKG712 is a novel bispecific biologic molecule specifically designed for ocular use in retinal diseases. It is composed of a vascular endothelial growth factor (VEGF)-inhibiting humanized monoclonal antibody fused with an angiopoietin-2 (Ang-2) antagonist peptide, forming a recombinant fusion protein. This dual-targeting approach enables simultaneous inhibition of VEGF and Ang-2 pathways, both of which are implicated in pathological neovascularization and vascular instability seen in conditions such as neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema. Preclinical studies have demonstrated robust efficacy, strong binding affinity to VEGF and Ang-2, favorable ocular pharmacokinetics, and an anticipated safety profile supporting further clinical development[1][5][6][8][9]. The drug aims to improve clinical outcomes by reducing the frequency of intravitreal injections compared to current anti-VEGF monotherapies.

Brand names

VIS-101VIS101VIS 101

Other names

AM 712AM712AM-712ASKG 712ASKG712ASKG-712